{"document_type": "article", "snippet": "Eric T. Schneiderman has begun an inquiry into whether Turing Pharmaceuticals violated antitrust rules by restricting distribution of a drug, Daraprim, as a way to thwart generic competition.", "type_of_material": "News", "web_url": "http://www.nytimes.com/2015/10/13/business/new-york-attorney-general-examining-if-turing-restricted-drug-access.html", "subsection_name": null, "blog": [], "section_name": "Business Day", "source": "The New York Times", "pub_date": "2015-10-13T00:00:00Z", "word_count": "785", "slideshow_credits": null, "news_desk": "Business", "byline": {"person": [{"role": "reported", "lastname": "POLLACK", "rank": 1, "organization": "", "firstname": "Andrew"}], "contributor": "", "original": "By ANDREW POLLACK"}, "abstract": "New York State Atty Gen Eric T Schneiderman starts investigation into Turing Pharmaceuticals, which skyrocketed price of infection drug, causing backlash against high pharmaceutical prices; Schneiderman's office has addressed letter of inquiry directly to Turing head Martin Shkreli. ", "keywords": [{"value": "Turing Pharmaceuticals AG", "rank": "1", "name": "organizations", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "rank": "2", "name": "subject", "is_major": "Y"}, {"value": "New York State", "rank": "3", "name": "glocations", "is_major": "Y"}, {"value": "Schneiderman, Eric T", "rank": "4", "name": "persons", "is_major": "Y"}, {"value": "Shkreli, Martin (1983- )", "rank": "5", "name": "persons", "is_major": "Y"}, {"value": "Prices (Fares, Fees and Rates)", "rank": "6", "name": "subject", "is_major": "N"}], "print_page": "4", "multimedia": [{"subtype": "wide", "legacy": {"wideheight": "126", "wide": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbWide.jpg", "widewidth": "190"}, "type": "image", "width": 190, "height": 126, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbWide.jpg"}, {"subtype": "xlarge", "legacy": {"xlargeheight": "400", "xlargewidth": "600", "xlarge": "images/2015/10/13/business/13drug-web1/13drug-web1-articleLarge.jpg"}, "type": "image", "width": 600, "height": 400, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-articleLarge.jpg"}, {"subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbStandard-v4.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "type": "image", "width": 75, "height": 75, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbStandard-v4.jpg"}], "lead_paragraph": "Eric T. Schneiderman has begun an inquiry into whether Turing Pharmaceuticals violated antitrust rules by restricting distribution of a drug, Daraprim, as a way to thwart generic competition.", "headline": {"print_headline": "New York Attorney General Examining if Turing Restricted Drug Access", "main": "New York Attorney General Examining Whether Turing Restricted Drug Access"}, "_id": "561c538238f0d84d2f3b8ac8"}